Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Dendritic cells, T cell tolerance and therapy of adverse immune reactions|
|Citation:||Clinical and Experimental Immunology, 2003; 133(1):1-10|
|Publisher:||Blackwell Publishing Ltd|
|Morel, P. A. ; Feili‐hariri, M. ; Coates, P. T. ; Thomson, A. W.|
|Abstract:||Dendritic cells (DC) are uniquely able to either induce immune responses or to maintain the state of self tolerance. Recent evidence has shown that the ability of DC to induce tolerance in the steady state is critical to the prevention of the autoimmune response. Likewise, DC have been shown to induce several type of regulatory T cells including Th2, Tr1, Ts and NKT cells, depending on the maturation state of the DC and the local microenvironment. DC have been shown to have therapeutic value in models of allograft rejection and autoimmunity, although no success has been reported in allergy. Several strategies, including the use of specific DC subsets, genetic modification of DC and the use of DC at various maturation stages for the treatment of allograft rejection and autoimmune disease are discussed. The challenge for the future use of DC therapy in human disease is to identify the appropriate DC for the proposed therapy; a task made more daunting by the extreme plasticity of DC that has recently been demonstrated. However, the progress achieved to date suggests that these are not insurmountable obstacles and that DC may become a useful therapeutic tool in transplantation and autoimmune disease.|
|Appears in Collections:||Aurora harvest|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.